# Bone Biologics Corp: financial statements, quarterly

BBLG · Nasdaq · CIK 1419554 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bblg.md) · [Financials](/companies/bblg/financials.md) · [Filings](/companies/bblg/filings.md) · [Insiders](/companies/bblg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bblg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [447 d](/filings/0001493152-25-008383.md) | [246](/filings/0001641172-25-009746.md) | [350](/filings/0001493152-25-011993.md) | [430](/filings/0001493152-25-023563.md) | [1,105 d](/filings/0001493152-26-008564.md) | [424](/filings/0001493152-26-023163.md) | [192](/filings/0001493152-26-038482.md) | [188](/filings/0001493152-26-048571.md) | [257 d](/filings/0001493152-26-008564.md) | [142](/filings/0001493152-26-023163.md) | [309](/filings/0001493152-26-038482.md) | [243](/filings/0001493152-26-048571.md) |
| Operating income | $k | [(1,160) d](/filings/0001493152-25-008383.md) | [(904)](/filings/0001641172-25-009746.md) | [(810)](/filings/0001493152-25-011993.md) | [(951)](/filings/0001493152-25-023563.md) | [(1,555) d](/filings/0001493152-26-008564.md) | [(1,038)](/filings/0001493152-26-023163.md) | [(748)](/filings/0001493152-26-038482.md) | [(715)](/filings/0001493152-26-048571.md) | [(733) d](/filings/0001493152-26-008564.md) | [(805)](/filings/0001493152-26-023163.md) | [(808)](/filings/0001493152-26-038482.md) | [(666)](/filings/0001493152-26-048571.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,550) d](/filings/0001493152-25-008383.md) | [(866)](/filings/0001493152-25-023563.md) | [(784)](/filings/0001493152-25-023563.md) | [(941)](/filings/0001493152-25-023563.md) | [(1,522) d](/filings/0001493152-26-008564.md) | [(1,017)](/filings/0001493152-26-048571.md) | [(741)](/filings/0001493152-26-048571.md) | [(667)](/filings/0001493152-26-048571.md) | [(685) d](/filings/0001493152-26-008564.md) | [(766)](/filings/0001493152-26-048571.md) | [(774)](/filings/0001493152-26-048571.md) | [(618)](/filings/0001493152-26-048571.md) |
| Diluted EPS | $ per share | not reported | [(1.31)](/filings/0001641172-25-009746.md) | [(4.02)](/filings/0001493152-25-011993.md) | [(14.21)](/filings/0001493152-25-023563.md) | not reported | [(1.92)](/filings/0001493152-26-023163.md) | [(1.33)](/filings/0001493152-26-038482.md) | [(0.37)](/filings/0001493152-26-048571.md) | not reported | [(0.43)](/filings/0001493152-26-023163.md) | [(0.43)](/filings/0001493152-26-038482.md) | [(0.17)](/filings/0001493152-26-048571.md) |
| Basic EPS | $ per share | not reported | [(1.31)](/filings/0001641172-25-009746.md) | [(4.02)](/filings/0001493152-25-011993.md) | [(14.21)](/filings/0001493152-25-023563.md) | not reported | [(1.92)](/filings/0001493152-26-023163.md) | [(1.33)](/filings/0001493152-26-038482.md) | [(0.37)](/filings/0001493152-26-048571.md) | not reported | [(0.43)](/filings/0001493152-26-023163.md) | [(0.43)](/filings/0001493152-26-038482.md) | [(0.17)](/filings/0001493152-26-048571.md) |

- Revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [3,027](/filings/0001493152-25-008383.md) | [3,228](/filings/0001493152-24-019271.md) | [2,332](/filings/0001493152-24-030982.md) | [3,566](/filings/0001493152-24-046020.md) | [3,325](/filings/0001493152-26-008564.md) | [2,747](/filings/0001641172-25-009746.md) | [6,640](/filings/0001493152-25-011993.md) | [6,049](/filings/0001493152-25-023563.md) | [5,334](/filings/0001493152-26-048571.md) | [4,530](/filings/0001493152-26-023163.md) | [4,032](/filings/0001493152-26-038482.md) | [6,088](/filings/0001493152-26-048571.md) |
| Current assets | $k | [3,738](/filings/0001493152-25-008383.md) | [3,840](/filings/0001493152-24-019271.md) | [3,193](/filings/0001493152-24-030982.md) | [4,066](/filings/0001493152-24-046020.md) | [3,861](/filings/0001493152-26-008564.md) | [3,162](/filings/0001641172-25-009746.md) | [7,002](/filings/0001493152-25-011993.md) | [6,351](/filings/0001493152-25-023563.md) | [5,796](/filings/0001493152-26-048571.md) | [4,979](/filings/0001493152-26-023163.md) | [4,437](/filings/0001493152-26-038482.md) | [6,432](/filings/0001493152-26-048571.md) |
| Total assets | $k | [3,738](/filings/0001493152-25-008383.md) | [3,840](/filings/0001493152-24-019271.md) | [3,193](/filings/0001493152-24-030982.md) | [4,066](/filings/0001493152-24-046020.md) | [3,861](/filings/0001493152-26-008564.md) | [3,162](/filings/0001641172-25-009746.md) | [7,002](/filings/0001493152-25-011993.md) | [6,351](/filings/0001493152-25-023563.md) | [5,796](/filings/0001493152-26-048571.md) | [4,979](/filings/0001493152-26-023163.md) | [4,437](/filings/0001493152-26-038482.md) | [6,432](/filings/0001493152-26-048571.md) |
| Current liabilities | $k | [831](/filings/0001493152-25-008383.md) | [165](/filings/0001493152-24-019271.md) | [285](/filings/0001493152-24-030982.md) | [273](/filings/0001493152-24-046020.md) | [378](/filings/0001493152-26-008564.md) | [251](/filings/0001641172-25-009746.md) | [406](/filings/0001493152-25-011993.md) | [334](/filings/0001493152-25-023563.md) | [419](/filings/0001493152-26-048571.md) | [309](/filings/0001493152-26-023163.md) | [512](/filings/0001493152-26-038482.md) | [481](/filings/0001493152-26-048571.md) |
| Total liabilities | $k | [831](/filings/0001493152-25-008383.md) | [165](/filings/0001493152-24-019271.md) | [285](/filings/0001493152-24-030982.md) | [273](/filings/0001493152-24-046020.md) | [378](/filings/0001493152-26-008564.md) | [251](/filings/0001641172-25-009746.md) | [406](/filings/0001493152-25-011993.md) | [334](/filings/0001493152-25-023563.md) | [419](/filings/0001493152-26-048571.md) | [309](/filings/0001493152-26-023163.md) | [512](/filings/0001493152-26-038482.md) | [481](/filings/0001493152-26-048571.md) |
| Shareholders' equity | $k | [2,906](/filings/0001493152-26-008564.md) | [3,675](/filings/0001493152-25-023563.md) | [2,909](/filings/0001493152-25-023563.md) | [3,792](/filings/0001493152-25-023563.md) | [3,484](/filings/0001493152-26-048571.md) | [2,911](/filings/0001493152-26-048571.md) | [6,596](/filings/0001493152-26-048571.md) | [6,017](/filings/0001493152-26-048571.md) | [5,378](/filings/0001493152-26-048571.md) | [4,670](/filings/0001493152-26-048571.md) | [3,925](/filings/0001493152-26-048571.md) | [5,952](/filings/0001493152-26-048571.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,018) d](/filings/0001493152-25-008383.md) | [(1,303)](/filings/0001641172-25-009746.md) | [(896) d](/filings/0001493152-25-011993.md) | [(572) d](/filings/0001493152-25-023563.md) | [(1,353) d](/filings/0001493152-26-008564.md) | [(926)](/filings/0001493152-26-023163.md) | [(459) d](/filings/0001493152-26-038482.md) | [(591) d](/filings/0001493152-26-048571.md) | [(715) d](/filings/0001493152-26-008564.md) | [(804)](/filings/0001493152-26-023163.md) | [(518) d](/filings/0001493152-26-038482.md) | [(532) d](/filings/0001493152-26-048571.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [67.2](/filings/0001493152-24-019271.md) | [339](/filings/0001493152-24-030982.md) | [392](/filings/0001493152-24-046020.md) | [661](/filings/0001641172-25-009746.md) | [195](/filings/0001493152-25-011993.md) | [292](/filings/0001493152-25-023563.md) | [531](/filings/0001493152-26-023163.md) | [558](/filings/0001493152-26-038482.md) | [1,795](/filings/0001493152-26-048571.md) | [1,795](/filings/0001493152-26-023163.md) | [1,797](/filings/0001493152-26-038482.md) | [3,737](/filings/0001493152-26-048571.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,389,057 at 2026-10-26, from the cover of the [10-Q filed 2026-10-26](/filings/0001493152-26-048571.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 26, 2026, 17:12 ET. No prices; not investment advice.